trial

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCTId NCT00591318
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Terminated
Enrollment 12 (actual)
Sponsored by Research Foundation for Mental Hygiene, Inc.
Primary completion 2011-03-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-10-10
Primary completion
2011-03-02
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ceftriaxone

Sponsors

Research Foundation for Mental Hygiene, Inc.Lead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
New York State Psychiatric Institute, Washington Heights Community ServiceCollaborator

Investigators

1
Brian A Fallon, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis — primary completion2011-03-02

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1,PHASE2
Primary Completion Date
2011-03-02
Status
TERMINATED
relationships
The graph out of here
drug
ceftriaxone
drug
lead_sponsor
Research Foundation for Mental Hygiene, Inc.
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
New York State Psychiatric Institute, Washington Heights Community Service
company
indication
Schizoaffective Disorder
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Brian A Fallon, MD
person